Savitha M. Rao

Array ( [id] => 14338665 [patent_doc_number] => 20190151305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => COMBINATION PRODUCT [patent_app_type] => utility [patent_app_number] => 16/062443 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11527135 [patent_doc_number] => 20170087112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE' [patent_app_type] => utility [patent_app_number] => 15/371787 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14348 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15371787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16229365 [patent_doc_number] => 10736895 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Cerdulatinib for treating hematological cancers [patent_app_type] => utility [patent_app_number] => 15/780414 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16364 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15780414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12542958 [patent_doc_number] => 10010519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-03 [patent_title] => Compositions and methods of use of phorbol esters for the treatment of stroke [patent_app_type] => utility [patent_app_number] => 15/358388 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13519 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15358388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18477090 [patent_doc_number] => 11690814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-04 [patent_title] => Suplatast tosilate for use in the treatment of cough associated with interstitial lung disease [patent_app_type] => utility [patent_app_number] => 16/061572 [patent_app_country] => US [patent_app_date] => 2016-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8057 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467717 [patent_doc_number] => 20190185501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => NEW MOLECULES FROM SEAWEEDS WITH ANTI-CANCER ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/776783 [patent_app_country] => US [patent_app_date] => 2016-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618280 [patent_doc_number] => 20170128468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'PHOSPHATIDYLGLYCEROL AS AN ANTI-INFLAMMATORY' [patent_app_type] => utility [patent_app_number] => 15/347491 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15354 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15347491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712605 [patent_doc_number] => 20190247366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => METHODS AND COMPOSITIONS FOR PROMOTING ADULT NEUROGENESIS [patent_app_type] => utility [patent_app_number] => 15/774456 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15774456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15945979 [patent_doc_number] => 10660867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Beta-hydroxyketones as topical active ingredients for the prevention or treatment of photodermatoses [patent_app_type] => utility [patent_app_number] => 15/778747 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3370 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11441819 [patent_doc_number] => 20170042840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'USE OF 1,3-PROPANEDISULFONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF SARCOIDOSIS' [patent_app_type] => utility [patent_app_number] => 15/335289 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5698 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15335289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13853861 [patent_doc_number] => 10188636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => Betahistine for the treatment of neurodegenerative diseases [patent_app_type] => utility [patent_app_number] => 15/332189 [patent_app_country] => US [patent_app_date] => 2016-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 5526 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15332189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11567362 [patent_doc_number] => 20170106006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'Neuroprotection by Mitochondria-Targeted Metformin' [patent_app_type] => utility [patent_app_number] => 15/294083 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11206 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15294083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11663566 [patent_doc_number] => 20170152285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'EXTRACTING METHOD OF KUGUACIN, PHARMACEUTICAL COMPOSITION COMPRISING THE KUGUACIN AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/284679 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 9376 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15284679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542585 [patent_doc_number] => 20170096411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/281679 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48584 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11512904 [patent_doc_number] => 20170079977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'METHODS FOR TREATING COGNITIVE DEFICITS ASSOCIATED WITH FRAGILE X SYNDROME' [patent_app_type] => utility [patent_app_number] => 15/274983 [patent_app_country] => US [patent_app_date] => 2016-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 21742 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15274983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13137355 [patent_doc_number] => 10085988 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-10-02 [patent_title] => Aglaroxin C and derivatives as HCV entry inhibitors [patent_app_type] => utility [patent_app_number] => 15/269886 [patent_app_country] => US [patent_app_date] => 2016-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 6101 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15269886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12831706 [patent_doc_number] => 20180169074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => Azophenols as ERG Oncogene Inhibitors [patent_app_type] => utility [patent_app_number] => 15/561626 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618210 [patent_doc_number] => 20170128397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'THREONATE COMPOUNDS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/258794 [patent_app_country] => US [patent_app_date] => 2016-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 22345 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662535 [patent_doc_number] => 20170151242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS' [patent_app_type] => utility [patent_app_number] => 15/257366 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7916 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383417 [patent_doc_number] => 20180243250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => METHOD OF TREATING A DOPAMINE RELATED DISORDER IN A SUBJECT BY ADMINISTERING LEVODOPA, IN COMBINATION WITH A DOPAMINE DECARBOXYLASE INHIBITOR AND A CATECHOL-O-METHYLTRANSFERASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 15/757217 [patent_app_country] => US [patent_app_date] => 2016-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757217 [rel_patent_id] =>[rel_patent_doc_number] =>)